$1.78
9.20% day before yesterday
Nasdaq, Nov 28, 10:17 pm CET
ISIN
US6904691010
Symbol
OVID

Ovid Therapeutics Inc. Stock price

$1.78
+0.29 19.46% 1M
+1.49 512.10% 6M
+0.85 90.64% YTD
+0.67 60.36% 1Y
-0.05 2.73% 3Y
-5.06 73.98% 5Y
-10.47 85.47% 10Y
-10.47 85.47% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.15 9.20%
ISIN
US6904691010
Symbol
OVID
Industry

Key metrics

Basic
Market capitalization
$126.8m
Enterprise Value
$101.2m
Net debt
positive
Cash
$25.6m
Shares outstanding
71.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
19.2 | 19.0
EV/Sales
15.3 | 15.1
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
74.0%
Return on Equity
-38.7%
ROCE
-71.6%
ROIC
-114.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$6.6m | $6.7m
EBITDA
$-41.3m | $-58.7m
EBIT
$-40.9m | $-41.1m
Net Income
$-36.3m | $-33.2m
Free Cash Flow
$-37.9m
Growth (TTM | estimate)
Revenue
949.2% | 1,073.5%
EBITDA
39.2% | 4.3%
EBIT
41.1% | 33.6%
Net Income
-11.8% | -25.8%
Free Cash Flow
34.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-624.3% | -876.8%
EBIT
-618.3%
Net
-549.6% | -496.9%
Free Cash Flow
-573.8%
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
5.9%
Employees
23
Rev per Employee
$20.0k
Show more

Is Ovid Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Ovid Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Ovid Therapeutics Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Ovid Therapeutics Inc. forecast:

Buy
93%
Hold
7%

Financial data from Ovid Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
6.61 6.61
949% 949%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
21% 21%
341%
- Research and Development Expense 25 25
40% 40%
377%
-41 -41
39% 39%
-624%
- Depreciation and Amortization -0.40 -0.40
128% 128%
-6%
EBIT (Operating Income) EBIT -41 -41
41% 41%
-618%
Net Profit -36 -36
12% 12%
-550%

In millions USD.

Don't miss a Thing! We will send you all news about Ovid Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ovid Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
17 days ago
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong inhibitory activity and a potential best-in-category safety profile in a Phase 1 study, supporting advancement into planned Phase 2 patient studies OV329 Pha...
Neutral
Seeking Alpha
about 2 months ago
Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Ritu Baral - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division...
Neutral
GlobeNewsWire
about 2 months ago
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exe...
More Ovid Therapeutics Inc. News

Company Profile

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Head office United States
CEO Jeremy Levin
Employees 23
Founded 2014
Website ovidrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today